India Viral Vector Manufacturing Market Size & Outlook, 2025-2033
India Viral Vector Manufacturing Market Insights
- According to Reed Intelligence analysis, the India Viral Vector Manufacturing Market size was USD 13.17 Million in 2024 and is projected to reach USD 53.49 Million by 2033.
- The India market is projected to grow at a CAGR of 16.79% between 2025 and 2033.
- By segment, Viral Vectors emerged as the largest By Type in terms of market size in 2024.
- Viral Vectors is anticipated to remain the most attractive By Type segment, recording the fastest growth during the forecast period.
![India Viral Vector Manufacturing Market Size, Share & Growth Analysis By [2033]](https://reedintelligence.com/uploads/charts/india-viral-vector-manufacturing-market-india-by-type-39603.png)
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- As of 2024, India held 4.92% of the global Viral Vector Manufacturing Market size.
- By 2033, United States is anticipated to capture the largest share of the global Viral Vector Manufacturing Market.
- In Asia Pacific, China is expected to lead the regional Viral Vector Manufacturing Market size by 2033.
- South Korea will remain the fastest-growing market in Asia Pacific, reaching USD 17.17 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 13.17 Million |
| Market Size In 2033 | USD 53.49 Million |
| Largest segment | Viral Vectors |
| Units | Revenue in USD Million |
| CAGR | 16.79% (2025-2033) |
| Segmnetation Covered | |
| By Type |
|
| By Workflow |
|
| By Application |
|
| By Disease |
|
| By End User |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
India Viral Vector Manufacturing Market By Type 2025-2033 (USD Million)
| By Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viral Vectors | XX.x | XX.x | XX.x | 8.47 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Plasmid DNA | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
India Viral Vector Manufacturing Market By Workflow 2025-2033 (USD Million)
| By Workflow | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upstream Manufacturing | XX.x | XX.x | XX.x | 8.37 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Downstream Manufacturing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
India Viral Vector Manufacturing Market By Application 2025-2033 (USD Million)
| By Application | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gene Therapy | XX.x | XX.x | XX.x | 7.28 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Vaccinology | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
India Viral Vector Manufacturing Market By Disease 2025-2033 (USD Million)
| By Disease | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cancer | XX.x | XX.x | XX.x | 6.5 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Genetic Disorders | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Infectious Diseases | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
India Viral Vector Manufacturing Market By End User 2025-2033 (USD Million)
| By End User | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceutical and Biopharmaceutical Companies | XX.x | XX.x | XX.x | 5.93 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Academics and Research Institutes | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
